ATE499364T1 - Hemmer der akt aktivität - Google Patents
Hemmer der akt aktivitätInfo
- Publication number
- ATE499364T1 ATE499364T1 AT05734336T AT05734336T ATE499364T1 AT E499364 T1 ATE499364 T1 AT E499364T1 AT 05734336 T AT05734336 T AT 05734336T AT 05734336 T AT05734336 T AT 05734336T AT E499364 T1 ATE499364 T1 AT E499364T1
- Authority
- AT
- Austria
- Prior art keywords
- compounds
- activity inhibitor
- act activity
- directed
- act
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US56116704P | 2004-04-09 | 2004-04-09 | |
PCT/US2005/011687 WO2005100344A1 (en) | 2004-04-09 | 2005-04-05 | Inhibitors of akt activity |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE499364T1 true ATE499364T1 (de) | 2011-03-15 |
Family
ID=35149934
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT05734336T ATE499364T1 (de) | 2004-04-09 | 2005-04-05 | Hemmer der akt aktivität |
Country Status (9)
Country | Link |
---|---|
US (2) | US7655649B2 (de) |
EP (1) | EP1737843B1 (de) |
JP (1) | JP2007532558A (de) |
CN (1) | CN1942465A (de) |
AT (1) | ATE499364T1 (de) |
AU (1) | AU2005233584B2 (de) |
CA (1) | CA2561311A1 (de) |
DE (1) | DE602005026509D1 (de) |
WO (1) | WO2005100344A1 (de) |
Families Citing this family (63)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1737861A4 (de) | 2004-04-09 | 2010-04-28 | Merck Sharp & Dohme | Hemmer der akt aktivität |
US7858800B2 (en) * | 2004-06-30 | 2010-12-28 | Banyu Pharmaceutical Co., Ltd. | Biaryl derivatives |
WO2006036395A2 (en) * | 2004-08-23 | 2006-04-06 | Merck & Co., Inc. | Inhibitors of akt activity |
WO2006123182A2 (en) | 2005-05-17 | 2006-11-23 | Merck Sharp & Dohme Limited | Cyclohexyl sulphones for treatment of cancer |
US8501739B2 (en) | 2005-07-04 | 2013-08-06 | High Point Pharmaceuticals, Llc | Medicaments |
AU2006322707B2 (en) | 2005-12-07 | 2011-09-15 | Sumitomo Chemical Company, Limited | Pyridazine compound and use thereof |
EP1978964A4 (de) | 2006-01-24 | 2009-12-09 | Merck & Co Inc | Jak2-tyrosinkinase-hemmung |
PT2402319T (pt) | 2006-03-31 | 2017-12-11 | Novartis Ag | Inibidores de dgat |
KR20090040259A (ko) | 2006-05-29 | 2009-04-23 | 하이 포인트 파마슈티칼스, 엘엘씨 | 3-(1,3-벤조디옥솔-5-일)-6-(4-시클로프로필피페라진-1-일)-피리다진, 그것의 염과 용매화합물 및 그것의 히스타민 h3 수용체 안타고니스트로서의 용도 |
AR064010A1 (es) * | 2006-12-06 | 2009-03-04 | Merck & Co Inc | Inhibidores de la actividad de la akt |
US20100022573A1 (en) * | 2006-12-06 | 2010-01-28 | Layton Mark E | Inhibitors of akt activity |
WO2008070823A2 (en) * | 2006-12-07 | 2008-06-12 | University Of South Florida | Substrate-mimetic akt inhibitor |
EP2014656A3 (de) | 2007-06-11 | 2011-08-24 | High Point Pharmaceuticals, LLC | Neue heterocyclische H3-Antagonisten |
PE20090596A1 (es) * | 2007-08-14 | 2009-06-07 | Bayer Schering Pharma Ag | Imidazoles biciclicos fusionados |
EP2062893A1 (de) * | 2007-10-18 | 2009-05-27 | Bayer Schering Pharma AG | Fusionierte Imidazole zur Behandlung von Krebs |
ES2396177T3 (es) * | 2007-08-14 | 2013-02-19 | Bayer Intellectual Property Gmbh | Pirimidinas bicíclicas fusionadas |
US20100048913A1 (en) | 2008-03-14 | 2010-02-25 | Angela Brodie | Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens;Synthesis In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity |
CA2726358A1 (en) * | 2008-06-03 | 2009-12-10 | Merck Sharp & Dohme Corp. | Inhibitors of akt activity |
JP2011522048A (ja) * | 2008-06-03 | 2011-07-28 | メルク・シャープ・エンド・ドーム・コーポレイション | Akt活性の阻害剤 |
US20110312916A1 (en) | 2009-02-05 | 2011-12-22 | Tokai Pharmaceuticals, Inc. | Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens |
ES2435804T3 (es) | 2009-02-13 | 2013-12-23 | Bayer Intellectual Property Gmbh | Pirimidinas condensadas como inhibidores de Akt |
EP2396330B1 (de) | 2009-02-13 | 2016-04-06 | Bayer Intellectual Property GmbH | Kondensierte pyrimidine |
EP2405756B1 (de) | 2009-03-12 | 2013-07-03 | Merck Sharp & Dohme Corp. | Hemmer der akt-aktivität |
WO2010114780A1 (en) | 2009-04-01 | 2010-10-07 | Merck Sharp & Dohme Corp. | Inhibitors of akt activity |
WO2011046771A1 (en) | 2009-10-14 | 2011-04-21 | Schering Corporation | SUBSTITUTED PIPERIDINES THAT INCREASE p53 ACTIVITY AND THE USES THEREOF |
SG181757A1 (en) * | 2009-12-28 | 2012-07-30 | Dev Center Biotechnology | Novel pyrimidine compounds as mtor and pi3k inhibitors |
US9315491B2 (en) | 2009-12-28 | 2016-04-19 | Development Center For Biotechnology | Pyrimidine compounds as mTOR and PI3K inhibitors |
WO2011130921A1 (en) * | 2010-04-23 | 2011-10-27 | Merck Sharp & Dohme Corp. | Inhibitors of akt activity |
EP2584903B1 (de) | 2010-06-24 | 2018-10-24 | Merck Sharp & Dohme Corp. | Neue heterozyklische verbindungen als erk-hemmer |
WO2012018754A2 (en) | 2010-08-02 | 2012-02-09 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF CATENIN (CADHERIN-ASSOCIATED PROTEIN), BETA 1 (CTNNB1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
EP3587574B1 (de) | 2010-08-17 | 2022-03-16 | Sirna Therapeutics, Inc. | Rna-interferenz-vermittelte hemmung der hepatitis b-virus (hbv)-genexpression mittels kurzer interferierender nukleinsäure (sina) |
WO2012030685A2 (en) | 2010-09-01 | 2012-03-08 | Schering Corporation | Indazole derivatives useful as erk inhibitors |
EP2632472B1 (de) | 2010-10-29 | 2017-12-13 | Sirna Therapeutics, Inc. | Durch rna-interferenz vermittelte inhibition einer genexpression unter verwendung von short-interfering-nukleinsäuren (sina) |
WO2012087772A1 (en) | 2010-12-21 | 2012-06-28 | Schering Corporation | Indazole derivatives useful as erk inhibitors |
CN103889962B (zh) | 2011-04-01 | 2017-05-03 | 犹他大学研究基金会 | 作为受体酪氨酸激酶btk抑制剂的取代的n‑(3‑(嘧啶‑4‑基)苯基)丙烯酰胺类似物 |
WO2012135800A1 (en) * | 2011-04-01 | 2012-10-04 | University Of Utah Research Foundation | Substituted n-phenylpyrimidin-2-amine analogs as inhibitors of the axl kinase |
CA2830367C (en) * | 2011-04-06 | 2016-08-30 | Taiho Pharmaceutical Co., Ltd. | Novel imidazo-oxazine compound or salt thereof |
JO3068B1 (ar) | 2011-04-07 | 2017-03-15 | Bayer Ip Gmbh | إيميدازوبيريميدينات كمثبطات كيناز akt |
US9023865B2 (en) | 2011-10-27 | 2015-05-05 | Merck Sharp & Dohme Corp. | Compounds that are ERK inhibitors |
US9408885B2 (en) | 2011-12-01 | 2016-08-09 | Vib Vzw | Combinations of therapeutic agents for treating melanoma |
EP3919620A1 (de) | 2012-05-02 | 2021-12-08 | Sirna Therapeutics, Inc. | Zusammensetzungen mit kurzer interferierender nukleinsäure (sina) |
US9233979B2 (en) | 2012-09-28 | 2016-01-12 | Merck Sharp & Dohme Corp. | Compounds that are ERK inhibitors |
EP3680238A1 (de) | 2012-10-04 | 2020-07-15 | University of Utah Research Foundation | Substituierte n-(3-(pyrimidin-4-yl-)phenyl-)acrylamid-analoga als tyrosinrezeptorkinase-btk-inhibitoren |
KR20150067298A (ko) | 2012-10-04 | 2015-06-17 | 유니버시티 오브 유타 리서치 파운데이션 | 티로신 수용체 키나아제 btk 억제제로서의 치환된 n-(3-(피리미딘-4-일)페닐)아크릴아미드 유사체 |
PL2925888T3 (pl) | 2012-11-28 | 2018-03-30 | Merck Sharp & Dohme Corp. | Kompozycje i sposoby do stosowania w leczeniu nowotworów |
CA2895504A1 (en) | 2012-12-20 | 2014-06-26 | Merck Sharp & Dohme Corp. | Substituted imidazopyridines as hdm2 inhibitors |
WO2014120748A1 (en) | 2013-01-30 | 2014-08-07 | Merck Sharp & Dohme Corp. | 2,6,7,8 substituted purines as hdm2 inhibitors |
BR112015022993B1 (pt) | 2013-03-14 | 2021-12-14 | Sumitomo Dainippon Pharma Oncology, Inc. | Inibidores de jak2 e alk2, composição farmacêutica compreendendo os referidos inibidores e uso destes |
US9884067B2 (en) | 2013-03-14 | 2018-02-06 | University Of Maryland, Baltimore | Androgen receptor down-regulating agents and uses thereof |
WO2015023710A1 (en) | 2013-08-12 | 2015-02-19 | Tokai Pharmaceuticals, Inc. | Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies |
US20160194368A1 (en) | 2013-09-03 | 2016-07-07 | Moderna Therapeutics, Inc. | Circular polynucleotides |
CA2971763A1 (en) * | 2014-12-23 | 2016-06-30 | Bergenbio Asa | Inhibitors of akt kinase |
US10323044B2 (en) | 2015-02-27 | 2019-06-18 | Taiho Pharmaceutical Co., Ltd. | Crystal of imidazo-oxazine, pharmaceutical composition containing said crystal, and method for producing said crystal |
US11883404B2 (en) | 2016-03-04 | 2024-01-30 | Taiho Pharmaceuticals Co., Ltd. | Preparation and composition for treatment of malignant tumors |
JOP20190055A1 (ar) | 2016-09-26 | 2019-03-24 | Merck Sharp & Dohme | أجسام مضادة ضد cd27 |
AU2018252546A1 (en) | 2017-04-13 | 2019-10-10 | Sairopa B.V. | Anti-SIRPα antibodies |
US10947234B2 (en) | 2017-11-08 | 2021-03-16 | Merck Sharp & Dohme Corp. | PRMT5 inhibitors |
WO2019148412A1 (en) | 2018-02-01 | 2019-08-08 | Merck Sharp & Dohme Corp. | Anti-pd-1/lag3 bispecific antibodies |
EP3773591A4 (de) | 2018-04-05 | 2021-12-22 | Sumitomo Dainippon Pharma Oncology, Inc. | Axl-kinase-inhibitoren und ihre verwendung |
EP3826684A4 (de) | 2018-07-26 | 2022-04-06 | Sumitomo Dainippon Pharma Oncology, Inc. | Verfahren zur behandlung von mit abnormaler acvr1 -expression verbundenen krankheiten und acvr1 -inhibitoren zur verwendung in demselben |
US11993602B2 (en) | 2018-08-07 | 2024-05-28 | Merck Sharp & Dohme Llc | PRMT5 inhibitors |
US11981701B2 (en) | 2018-08-07 | 2024-05-14 | Merck Sharp & Dohme Llc | PRMT5 inhibitors |
CA3160153A1 (en) | 2019-12-17 | 2021-06-24 | Michelle Machacek | Prmt5 inhibitors |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL115889A0 (en) | 1994-11-14 | 1996-01-31 | Rohm & Haas | Pyridazinones and their use as fungicides |
JP4361276B2 (ja) | 2001-04-10 | 2009-11-11 | メルク エンド カムパニー インコーポレーテッド | Akt活性の阻害物質 |
CA2480800C (en) | 2002-04-08 | 2008-09-23 | Mark T. Bilodeau | Inhibitors of akt activity |
WO2003086279A2 (en) * | 2002-04-08 | 2003-10-23 | Merck & Co., Inc. | Inhibitors of akt activity |
WO2003086403A1 (en) | 2002-04-08 | 2003-10-23 | Merck & Co., Inc. | Inhibitors of akt activity |
US20060142178A1 (en) * | 2002-04-08 | 2006-06-29 | Barnett Stanley F | Method of treating cancer |
US7273869B2 (en) | 2002-04-08 | 2007-09-25 | Merck & Co., Inc. | Inhibitors of Akt activity |
AU2002952121A0 (en) | 2002-10-17 | 2002-10-31 | Alchemia Limited | Novel carbohydrate based anti-bacterials |
DE60336576D1 (de) | 2002-10-30 | 2011-05-12 | Merck Sharp & Dohme | Hemmer der akt aktivität |
AU2004233827B2 (en) | 2003-04-24 | 2009-05-28 | Merck Sharp & Dohme Corp. | Inhibitors of Akt activity |
WO2004096135A2 (en) | 2003-04-24 | 2004-11-11 | Merck & Co., Inc. | Inhibitors of akt activity |
AU2004233828B2 (en) | 2003-04-24 | 2009-05-28 | Merck Sharp & Dohme Corp. | Inhibitors of Akt activity |
US7304063B2 (en) | 2003-04-24 | 2007-12-04 | Merck & Co., Inc. | Inhibitors of Akt activity |
EP1737861A4 (de) | 2004-04-09 | 2010-04-28 | Merck Sharp & Dohme | Hemmer der akt aktivität |
US20080058339A1 (en) * | 2006-08-30 | 2008-03-06 | Biovitrum | New compounds |
-
2005
- 2005-04-05 EP EP05734336A patent/EP1737843B1/de not_active Not-in-force
- 2005-04-05 JP JP2007507479A patent/JP2007532558A/ja active Pending
- 2005-04-05 DE DE602005026509T patent/DE602005026509D1/de active Active
- 2005-04-05 CN CNA2005800119768A patent/CN1942465A/zh active Pending
- 2005-04-05 US US11/547,367 patent/US7655649B2/en not_active Expired - Fee Related
- 2005-04-05 AT AT05734336T patent/ATE499364T1/de not_active IP Right Cessation
- 2005-04-05 AU AU2005233584A patent/AU2005233584B2/en not_active Ceased
- 2005-04-05 CA CA002561311A patent/CA2561311A1/en not_active Abandoned
- 2005-04-05 WO PCT/US2005/011687 patent/WO2005100344A1/en active Application Filing
-
2009
- 2009-11-18 US US12/621,124 patent/US8003643B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
US20100075970A1 (en) | 2010-03-25 |
CA2561311A1 (en) | 2005-10-27 |
US20080280889A1 (en) | 2008-11-13 |
DE602005026509D1 (de) | 2011-04-07 |
WO2005100344A1 (en) | 2005-10-27 |
JP2007532558A (ja) | 2007-11-15 |
EP1737843A4 (de) | 2009-01-28 |
EP1737843B1 (de) | 2011-02-23 |
AU2005233584A1 (en) | 2005-10-27 |
US7655649B2 (en) | 2010-02-02 |
AU2005233584B2 (en) | 2010-12-09 |
EP1737843A1 (de) | 2007-01-03 |
CN1942465A (zh) | 2007-04-04 |
US8003643B2 (en) | 2011-08-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE499364T1 (de) | Hemmer der akt aktivität | |
ATE461179T1 (de) | Hemmer der akt aktivität | |
ATE446752T1 (de) | Hemmer der akt aktivität | |
ATE512957T1 (de) | Hemmer der akt aktivität | |
WO2006036395A3 (en) | Inhibitors of akt activity | |
ATE503483T1 (de) | Hemmer der akt aktivität | |
ATE525375T1 (de) | Hemmer von janus-kinasen und/oder 3- phosphoinositid-abhängiger protein-kinase 1 | |
GEP20125368B (en) | Kinase inhibitors | |
ATE554087T1 (de) | Neue kinaseinhibitoren | |
ATE400274T1 (de) | Hemmstoffe der akt aktivität | |
HK1093159A1 (en) | Monocyclic heterocycles as kinase inhibitors | |
WO2003086279A3 (en) | Inhibitors of akt activity | |
EA200602100A1 (ru) | Соединения и способы для ингибирования митотической прогрессии | |
MY139689A (en) | Imidazotriazines as protein kinase inhibitors | |
WO2004096130A3 (en) | Inhibitors of akt activity | |
TW200801008A (en) | Protein kinase inhibitors | |
MX2010004263A (es) | Inhibidores de quinasa c-fms. | |
BRPI0517737A (pt) | inibidores de quinase | |
UA85087C2 (en) | Monocyclic heterocycles as kinase inhibitors | |
MXPA05009151A (es) | Inhibidores de cinasa heterociclica. | |
ATE527264T1 (de) | Kondensierte heterozyklische verbindungen als hemmer von proteinkinasen | |
TW200602023A (en) | Monocyclic heterocycles as kinase inhibitors | |
IL162820A (en) | Composition against tumors comprising substituted acryloyl distamycin derivatives and protein kinase (serine/threonine kinase) inhibitors | |
ATE540951T1 (de) | Substituierte 7,8-dihydro-1h-pyrimidoä4,5- büdiazepin-4-amine als kinase inhibitoren |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |